Trial · NCT04503707
Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice
NCT04503707, Completed, Ferring Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice. Trials, record NCT04503707. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04503707
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice
- NCT number
- NCT04503707
- Status
- Completed
- Enrollment
- 250 participants, actual
- Lead sponsor
- Ferring Pharmaceuticals
- Conditions
- Controlled Ovarian Stimulation
- Interventions
- Follitropin Delta
- First posted
- 2020-08-07
- Last updated
- 2021-12-14
Source ClinicalTrials.gov
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Daily dose of REKOVELLE administered (for naïve and non-naïve subjects) | At the end of the stimulation protocol (up to 30 days) | |
| Primary | Duration of treatment with REKOVELLE (for naïve and non-naïve subjects) | From first until last day of REKOVELLE treatment (up to 30 days) | |
| Primary | Use of the dosing App (for naïve and non-naïve subjects) | At visit when the daily dose of REKOVELLE is decided (up to 2 hours) | |
| Primary | Type of Gonadotropin-Releasing Hormone (GnRH) used (for naïve and non-naïve subjects) | At visit (up to 2 hours) during the REKOVELLE treatment period | |
| Primary | Duration of treatment with GnRH (for naïve and non-naïve subjects) | At the end of the ovarian controlled stimulation (up to 2 weeks) | |
| Primary | Treatment used for the triggering of follicle maturation (for naïve and non-naïve subjects) | At the last visit during the REKOVELLE treatment period (from 5 to 30 days) | |
| Primary | Treatment used for Luteal phase support (for naïve and non-naïve subjects) | From start of REKOVELLE treatment until 10-11 weeks after embryo transfer | Decided as a choice between Progesterone, Oestrogen and hCG |
| Secondary | Rate of Ongoing Pregnancy (for naïve and non-naïve subjects) | Up to 10-11 weeks after transfer | Ongoing pregnancy is defined as at least one intrauterine viable fetus, 10-11 weeks after first fresh or frozen embryo/blastocyst transfer. |
| Secondary | Number of oocytes retrieved (for naïve and non-naïve subjects) | At visit (up to 2 hours) at 36 hours after completed REKOVELLE treatment | |
| Secondary | Number of oocytes/embryos/blastocysts frozen (for naïve and non-naïve subjects) | At Day 3 after oocyte retrieval |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04503707
GET https://conductscience.org/api/trials/v1/NCT04503707/registered?page=2